Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Virna J A Schuck"'
Autor:
Nathalie H. Gosselin, Virna J. A. Schuck, Olivier Barriere, Kenneth Kulmatycki, Alison Margolskee, Patrick Smith, YanLing He
Publikováno v:
Clinical Pharmacology & Therapeutics. 113:328-338
Inclisiran is a novel N-acetylgalactosamine (GalNAc) conjugated small-interfering ribonucleic acid (siRNA) therapy designed to specifically target proprotein convertase subtilisin/kexin type 9 (PCSK9) mRNA in the liver for the treatment of hyperchole
Autor:
Edward J Mills, Jason A. Roberts, Alex Lepak, Debra Hanna, Mark J. Shelton, Kayla Ann Andrews, Craig R. Rayner, Lena E. Friberg, Patrick F. Smith, David Wesche, David R. Andes, Karen Rowland‐Yeo, Hartmut Derendorf, Virna J A Schuck, Thomas M. Polasek
Publikováno v:
Clinical Pharmacology and Therapeutics
Model-informed drug development (MIDD) has a long and rich history in infectious diseases. This review describes foundational principles of translational anti-infective pharmacology, including choice of appropriate measures of exposure and pharmacody
Autor:
Gregory S. Basarab, Marshall Morningstar, Sheila Irene Hauck, Gunther Kern, Amy Kimzey, Vincent Galullo, Peter Doig, Charles J. Eyermann, Karthick Vishwanathan, Amy Kutschke, Virna J A Schuck, Fei Zhou, Madhusudhan Reddy Gowravaram
Publikováno v:
Journal of Medicinal Chemistry. 63:11882-11901
Herein, we report spiropyrimidinetriones (SPTs) incorporating N-linked azole substituents on a benzisoxazole scaffold with improved Gram-positive antibacterial activity relative to previously described analogues. SPTs have an unusual spirocyclic arch
Autor:
Sherwin K. B. Sy, Marie-Eve Beaudoin, Wright W. Nichols, Virna J A Schuck, Huiming Xia, Hartmut Derendorf, Luning Zhuang
Publikováno v:
Journal of Antimicrobial Chemotherapy. 73:1295-1304
Objectives To characterize quantitatively the effect of avibactam in potentiating ceftazidime against MDR Pseudomonas aeruginosa by developing a mathematical model to describe the bacterial response to constant concentration time-kill information and
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology. 6:197-207
The combination of aztreonam-avibactam is active against multidrug-resistant Enterobacteriaceae that express metallo-β-lactamases. A complex synergistic interaction exists between aztreonam and avibactam bactericidal activities that have not been qu
Autor:
Hartmut Derendorf, Virna J A Schuck, Huiming Xia, Wright W. Nichols, Luning Zhuang, Sherwin K. B. Sy
Publikováno v:
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 25(7)
Objective The aim of the present work was to use a semi-mechanistic pharmacokinetic–pharmacodynamic (PK/PD) model developed from in vitro time–kill measurements with P. aeruginosa to compare different pharmacodynamic indices derived from simulate
Autor:
Majid Vakilynejad, Arijit Chakravarty, Tonika Bohnert, Anu Shilpa Krishnatry, Jerome T. Mettetal, Tristan S. Maurer, Christopher R. Gibson, Daniel R. Mudra, Edgar Schuck, Yaming Su, Marjoleen J.M.A Nijsen, Tycho Heimbach, Shining Wang, Virna J A Schuck, Cheng-Pang Hsu, Harvey Wong, Patrick Trapa, Joseph Raybon, Patricia Schroeder, Satyendra Suryawanshi, Jing Lin, Bianca M. Liederer, Valeriu Damian-Iordache, Alice Tsai
Publikováno v:
The AAPS Journal. 17:462-473
The application of modeling and simulation techniques is increasingly common in preclinical stages of the drug discovery and development process. A survey focusing on preclinical pharmacokinetic/pharmacodynamics (PK/PD) analysis was conducted across
Autor:
Howard B Haimes, Amy Kutschke, Gregory S. Basarab, Peter Doig, Vincent Galullo, John McNulty, Madhusudhan Reddy Gowravaram, Gregory G. Stone, Gunther Kern, Patrick Brassil, Virna J A Schuck
Publikováno v:
Journal of Medicinal Chemistry. 57:9078-9095
The compounds described herein with a spirocyclic architecture fused to a benzisoxazole ring represent a new class of antibacterial agents that operate by inhibition of DNA gyrase as corroborated in an enzyme assay and by the inhibition of precursor
Autor:
Andrew Hughes, Beesan Tan, James W.T. Yates, Rhys D.O. Jones, Lena Brynne, Ulf Bredberg, Virna J A Schuck, Simon T. Barry, Malin Aurell, Sandra A.G. Visser, Marie Cooke, Rasmus Jansson-Löfmark, Ann-Charlotte Egnell, Sheila Annie Peters
Publikováno v:
Drug Discovery Today. 18:764-775
Model-based drug discovery (MBDDx) aims to build and continuously improve the quantitative understanding of the relation between drug exposure (target engagement) efficacy and safety, to support target validation; to define compound property criteria
Autor:
Jared L. Crandon, Virna J A Schuck, Wright W. Nichols, Marie-Eve Beaudoin, Mary Anne Banevicius, David P. Nicolau, M. Angela Tanudra
Publikováno v:
Antimicrobial Agents and Chemotherapy. 56:6137-6146
The combination of ceftazidime and avibactam possesses potent activity against resistant Gram-negative pathogens, including Pseudomonas aeruginosa . We compared the efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam using a